Neurimmune today announced that two poster presentations related to ALXN2220 (formerly NI006) for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM) will be presented by Neurimmune and its collaborators in Lisbon at Heart Failure 2024, a scientific congress of the European Society of Cardiology (ESC). ALXN2220 is an investigational human monoclonal antibody designed to deplete amyloid deposits in ATTR-CM as add-on to standard of care.1,2
Presentation Details
Title: Initial safety of targeted immune activation with the amyloid depleter ALXN2220
Presenter: Thibaud Damy, University Hospital Henri Mondor
Session Type: Moderated ePosters
Date: May 12, 2024
Time: 11:00 – 11:45
Location: Moderated ePosters 1
Title: Prediction of cardiac ATTR depletion by ALXN2220 using mechanistic PK/PD modeling
Presenter: Peter Christian Kahr, Vice President, Clinical Development, Neurimmune
Session Type: ePosters
Date: May 13, 2024
Time: 9:00 – 17:00
Location: ePosters Screen 1
Amyloid transthyretin cardiomyopathy (ATTR-CM) is an underdiagnosed, systemic condition that leads to progressive heart failure and high rate of fatality within four years from diagnosis.3,4 Progressive ATTR amyloid depositions characterize the disease, causing heart failure and death. Despite recent advances and approved therapies, there remains significant unmet medical need in treating moderate to severe ATTR-CM, and amyloid depletion may constitute an important new mechanism to achieve further effectiveness.
In 2022, Neurimmune entered into an exclusive global collaboration and license agreement with Alexion, AstraZeneca Rare Disease, for ALXN2220. Neurimmune is responsible for completion of the Phase 1b clinical study on behalf of Alexion, with Alexion incurring certain trial costs. Aside from the Phase 1b trial, Alexion is responsible for further clinical development, manufacturing, and commercialization as ALXN2220. In 2024, Alexion initiated the Phase 3 DepleTTR-CM clinical study to assess the efficacy and safety of ALXN2220 for the treatment of ATTR-CM.
1Garcia-Pavia et al., N Engl J Med 2023; 389(3):239.
2Michalon et al., Nat Commun 2021; 12(1):3142.
3 Lauppe RE, et al. Open Heart. 2021 Oct;8(2):e001755.
4 González-Duarte A, et al. Neurol Ther. 2020;9(1):135-149.
About Neurimmune
Neurimmune is a biopharmaceutical company translating human immune memory into antibody therapeutics. Neurimmune develops drug candidates for CNS and related protein aggregation diseases including Alzheimer’s disease, amyotrophic lateral sclerosis, frontotemporal dementia and ATTR cardiomyopathy. Neurimmune discovered NI101SQ, a human monoclonal antibody to deplete brain amyloid of patients with Alzheimer’s disease. With its Reverse Translational MedicineTM technology, Neurimmune discovered the anti-SOD1 antibody AP-101 for ALS and the anti-ATTR antibody NI006 for ATTR cardiomyopathy, programs being currently evaluated in clinical trials.
Contact for Media
John Capodanno (US)
john.capodanno@dentonsglobaladvisors.com
Martin Meier-Pfister (Switzerland)
media@neurimmune.com
